相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization
Andrew J. Sawyer et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities
Jessie L. -S. Au et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Olaparib for the treatment of BRCA-mutated advanced ovarian cancer
Marklie Munroe et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2016)
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia
Rachel Thijssen et al.
BLOOD (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Role of the tumor stroma in resistance to anti-angiogenic therapy
Elisabeth J. M. Huijbers et al.
DRUG RESISTANCE UPDATES (2016)
Targeting collagen for diagnostic imaging and therapeutic delivery
Hendra Wahyudi et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Epithelial-mesenchymal transition: a new target in anticancer drug discovery
Fabrizio Marcucci et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
DNA repair targeted therapy: The past or future of cancer treatment?
Navnath S. Gavande et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism
Chengguang Zhao et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Joyce F. Liu et al.
CURRENT ONCOLOGY REPORTS (2016)
A second DNA binding site in human BRCA2 promotes homologous recombination
Catharina von Nicolai et al.
NATURE COMMUNICATIONS (2016)
Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
Miles A. Miller et al.
CANCER DISCOVERY (2016)
Targeting microenvironment in cancer therapeutics
Matthew Martin et al.
ONCOTARGET (2016)
DNA Damage Response and Immune Defense: Links and Mechanisms
Rania Nakad et al.
FRONTIERS IN GENETICS (2016)
A novel autophagy/mitophagy inhibitor liensinine sensitizes breast cancer cells to chemotherapy through DNM1L-mediated mitochondrial fission
Jing Zhou et al.
AUTOPHAGY (2015)
Inhibition of Mer and Axl receptor tyrosine kinases leads to increased apoptosis and improved chemosensitivity in human neuroblastoma
Yixin Li et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
PARP inhibitors in the management of breast cancer: current data and future prospects
Luca Livraghi et al.
BMC MEDICINE (2015)
Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy
Q. Tan et al.
BRITISH JOURNAL OF CANCER (2015)
Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960
A. S. Ahmad et al.
BRITISH JOURNAL OF CANCER (2015)
AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
Moshe Elkabets et al.
CANCER CELL (2015)
Mechanisms of Drug Resistance Related to the Microenvironment of Solid Tumors and Possible Strategies to Inhibit Them
Qian Tan et al.
CANCER JOURNAL (2015)
CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy
Jemima Escamilla et al.
CANCER RESEARCH (2015)
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
Toni M. Brand et al.
CLINICAL CANCER RESEARCH (2015)
Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways
Meredith A. Morgan et al.
CLINICAL CANCER RESEARCH (2015)
Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors
Chun-Han Lin et al.
MOLECULAR BIOLOGY OF THE CELL (2015)
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
Xiaofeng Zheng et al.
NATURE (2015)
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
Kari R. Fischer et al.
NATURE (2015)
SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer
Juan Vaz et al.
PANCREAS (2015)
ATM and ATR as therapeutic targets in cancer
Anika Maria Weber et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression
Xin Ye et al.
TRENDS IN CELL BIOLOGY (2015)
Profile of veliparib and its potential in the treatment of solid tumors
Lars M. Wagner
ONCOTARGETS AND THERAPY (2015)
Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)
Daruka Mahadevan et al.
ONCOTARGET (2015)
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Tomoe Higuchi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers
Yusuke Oku et al.
FEBS OPEN BIO (2015)
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Jonathan Pol et al.
ONCOIMMUNOLOGY (2015)
Overview of methods for overcoming hindrance to drug delivery to tumors, with special attention to tumor interstitial fluid
Gianfranco Baronzio et al.
FRONTIERS IN ONCOLOGY (2015)
First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma
Jordi Rodon et al.
CLINICAL CANCER RESEARCH (2015)
You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia
A. R. Sehgal et al.
LEUKEMIA (2015)
DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer
Denis Velic et al.
BIOMOLECULES (2015)
Molecular deconstruction, detection, and computational prediction of microenvironment-modulated cellular responses to cancer therapeutics
Mark A. LaBarge et al.
ADVANCED DRUG DELIVERY REVIEWS (2014)
AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Catherine Wilson et al.
CANCER RESEARCH (2014)
Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments
H. Inoue et al.
CELL DEATH AND DIFFERENTIATION (2014)
Molecular Pathways: HER3 Targeted Therapy
Kinisha Gala et al.
CLINICAL CANCER RESEARCH (2014)
Tumor Plasticity Interferes with Anti-Tumor Immunity
Salem Chouaib et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2014)
YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth
Boon Chuan Low et al.
FEBS LETTERS (2014)
Targeting DNA repair pathways for cancer treatment: what's new?
Mark R. Kelley et al.
FUTURE ONCOLOGY (2014)
Acquired resistance to EGFR-targeted therapies in colorectal cancer
Beth O. Van Emburgh et al.
MOLECULAR ONCOLOGY (2014)
Role of osteopontin in the pathophysiology of cancer
Lalita A. Shevde et al.
MATRIX BIOLOGY (2014)
The wound healing, chronic fibrosis, and cancer progression triad
Brad Rybinski et al.
PHYSIOLOGICAL GENOMICS (2014)
Targeting EMT in cancer: opportunities for pharmacological intervention
Felicity M. Davis et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma
Emmy D. G. Fleuren et al.
ONCOTARGET (2014)
A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype
Qing Cheng et al.
BREAST CANCER RESEARCH (2014)
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
Isabel Ben-Batalla et al.
BLOOD (2013)
Wogonoside induces cell cycle arrest and differentiation by affecting expression and subcellular localization of PLSCR1 in AML cells
Yan Chen et al.
BLOOD (2013)
Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer
N. J. Curtin
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Breast cancer stem cells and epithelial mesenchymal plasticity - Implications for chemoresistance
Cletus A. Pinto et al.
CANCER LETTERS (2013)
ABL Regulation by AXL Promotes Cisplatin Resistance in Esophageal Cancer
Jun Hong et al.
CANCER RESEARCH (2013)
Targeting the Tumor Microenvironment for Cancer Therapy
Nor Eddine Sounni et al.
CLINICAL CHEMISTRY (2013)
Tumour heterogeneity and cancer cell plasticity
Corbin E. Meacham et al.
NATURE (2013)
Influence of tumour micro-environment heterogeneity on therapeutic response
Melissa R. Junttila et al.
NATURE (2013)
First Axl inhibitor enters clinical trials
Cormac Sheridan
NATURE BIOTECHNOLOGY (2013)
Autophagy in Human Health and Disease REPLY
Augustine M. K. Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Min Yu et al.
SCIENCE (2013)
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
X. Sui et al.
CELL DEATH & DISEASE (2013)
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Cristina Montero-Conde et al.
CANCER DISCOVERY (2013)
MECHANISMS OF DISEASE Autophagy in Human Health and Disease
Augustine M. K. Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Upregulation of Drug Transporter Expression by Osteopontin in Prostate Cancer Cells
I-Shan Hsieh et al.
MOLECULAR PHARMACOLOGY (2013)
Lys05 A new lysosomal autophagy inhibitor
Ravi K. Amaravadi et al.
AUTOPHAGY (2012)
Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells
Weijia Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
Paolo P. Provenzano et al.
CANCER CELL (2012)
Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)
Cristina Oliveras-Ferraros et al.
CELL CYCLE (2012)
The extracellular matrix: A dynamic niche in cancer progression
Pengfei Lu et al.
JOURNAL OF CELL BIOLOGY (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeting Epigenetic Readers in Cancer
Mark A. Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells
Brian Budke et al.
NUCLEIC ACIDS RESEARCH (2012)
Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity to Chemoradiotherapy in Non-Small Cell Lung Cancer
Yasushi Shintani et al.
ANNALS OF THORACIC SURGERY (2011)
The ins and Outs of the Epithelial to Mesenchymal Transition in Health and Disease
M. Angela Nieto
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, VOL 27 (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
A systems view of epithelial-mesenchymal transition signaling states
Stuart Thomson et al.
CLINICAL & EXPERIMENTAL METASTASIS (2011)
The controversial role of ABC transporters in clinical oncology
Akina Tamaki et al.
ESSAYS IN BIOCHEMISTRY: ABC TRANSPORTERS (2011)
ABC transporters, mechanisms and biology: an overview
I. Barry Holland
ESSAYS IN BIOCHEMISTRY: ABC TRANSPORTERS (2011)
Role of YAP/TAZ in mechanotransduction
Sirio Dupont et al.
NATURE (2011)
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression
Mina J. Bissell et al.
NATURE MEDICINE (2011)
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
Joan T. Garrett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors
Mark J. Anderton et al.
TOXICOLOGIC PATHOLOGY (2011)
Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies
Beata Holkova et al.
EXPERT REVIEW OF HEMATOLOGY (2011)
Mechanisms of AXL overexpression and function in Imatinibresistant chronic myeloid leukemia cells
Maeva Dufies et al.
ONCOTARGET (2011)
Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner
Neta Erez et al.
CANCER CELL (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kai Kessenbrock et al.
CELL (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Tumors as Organs: Complex Tissues that Interface with the Entire Organism
Mikala Egeblad et al.
DEVELOPMENTAL CELL (2010)
Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance
Zhiwei Wang et al.
DRUG RESISTANCE UPDATES (2010)
Hallmarks of cancer: Interactions with the tumor stroma
Kristian Pietras et al.
EXPERIMENTAL CELL RESEARCH (2010)
The DNA Damage Response: Making It Safe to Play with Knives
Alberto Ciccia et al.
MOLECULAR CELL (2010)
Termination of autophagy and reformation of lysosomes regulated by mTOR
Li Yu et al.
NATURE (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance
Hiroshi Tanaka et al.
NATURE MEDICINE (2010)
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
A. Singh et al.
ONCOGENE (2010)
Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma
Michiro Susa et al.
PLOS ONE (2010)
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
Christine Gjerdrum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
ABC transporters in cancer: more than just drug efflux pumps
Jamie I. Fletcher et al.
NATURE REVIEWS CANCER (2010)
Regulation Mechanisms and Signaling Pathways of Autophagy
Congcong He et al.
ANNUAL REVIEW OF GENETICS (2009)
PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
Yongping Crawford et al.
CANCER CELL (2009)
A Stiff Blow from the Stroma: Collagen Crosslinking Drives Tumor Progression
Mei Rosa Ng et al.
CANCER CELL (2009)
Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
Li Liu et al.
CANCER RESEARCH (2009)
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Thiruvengadam Arumugam et al.
CANCER RESEARCH (2009)
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Kandice R. Levental et al.
CELL (2009)
Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Wei Wang et al.
CLINICAL CANCER RESEARCH (2009)
Validation of Lysyl Oxidase As a Prognostic Marker for Metastasis and Survival in Head and Neck Squamous Cell Carcinoma: Radiation Therapy Oncology Group Trial 90-03
Quynh-Thu Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
Pierre Farmer et al.
NATURE MEDICINE (2009)
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
Chad J. Creighton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response
S. Cheetham et al.
BRITISH JOURNAL OF CANCER (2008)
Identification and characterization of ovarian cancer-initiating cells from primary human tumors
Shu Zhang et al.
CANCER RESEARCH (2008)
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors
Arkaitz Carracedo et al.
CELL CYCLE (2008)
SPARC in cancer biology: Its role in cancer progression and potential for therapy
Isabella T. Tai et al.
DRUG RESISTANCE UPDATES (2008)
Liver cirrhosis, other liver diseases, pancreatitis and subsequent cancer: record linkage study
Michael J. Goldacre et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2008)
Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells
Emilia Fransvea et al.
HEPATOLOGY (2008)
Stromal gene expression predicts clinical outcome in breast cancer
Greg Finak et al.
NATURE MEDICINE (2008)
A stromal gene signature associated with inflammatory breast cancer
Brenda J. Boersma et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Cell-matrix adhesion
Allison L. Berrier et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
Drug resistance and the solid tumor microenvironment
Olivier Tredan et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Fen1 mutations result in autoimmunity, chronic inflammation and cancers
Li Zheng et al.
NATURE MEDICINE (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells
Maria M. Ho et al.
CANCER RESEARCH (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
Role of ABCO in export of sphingosine-1-phosphate from mast cells
Poulami Mitra et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia
MHGP Raaijmakers et al.
CLINICAL CANCER RESEARCH (2006)
被撤回的出版物: Lysyl oxidase is essential for hypoxia-induced metastasis (Retracted article. See vol. 579, pg. 456, 2020)
JT Erler et al.
NATURE (2006)
Local force and geometry sensing regulate cell functions
V Vogel et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Targeting multidrug resistance in cancer
G Szakács et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Substrate rigidity regulates the formation and maintenance of tissues
WH Guo et al.
BIOPHYSICAL JOURNAL (2006)
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
GA Smolen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma
CT Miller et al.
ONCOGENE (2006)
Hepatocellular carcinoma pathogenesis: from genes to environment
Paraskevi A. Farazi et al.
NATURE REVIEWS CANCER (2006)
Expression of Axl in lung adenocarcinoma and correlation with tumor progression
YS Shieh et al.
NEOPLASIA (2005)
Tensional homeostasis and the malignant phenotype
MJ Paszek et al.
CANCER CELL (2005)
In vivo RNA interference -: Mediated ablation of MDR1 P-glycoprotein
A Pichler et al.
CLINICAL CANCER RESEARCH (2005)
Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy
IT Tai et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma
JS Campbell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Tumor-stroma interactions
NA Bhowmick et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
Molecular mechanisms of drug resistance
DB Longley et al.
JOURNAL OF PATHOLOGY (2005)
NF-κB activation in Esophageal adenocarcinoma -: Relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy
MMM Abdel-Latif et al.
ANNALS OF SURGERY (2004)
VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein
H Minderman et al.
CLINICAL CANCER RESEARCH (2004)
The stats of cancer - New molecular targets come of age
H Yu et al.
NATURE REVIEWS CANCER (2004)
A distinct side population of cells with high drug efflux capacity in human tumor cells
C Hirschmann-Jax et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Stromal fibroblasts in cancer initiation and progression
NA Bhowmick et al.
NATURE (2004)
Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia
T Matsunaga et al.
NATURE MEDICINE (2003)
Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis
S Grünert et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
T Holbro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Clinical update: proteasome inhibitors in hematologic malignancies
P Richardson
CANCER TREATMENT REVIEWS (2003)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells
PJ Real et al.
ONCOGENE (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Drug interaction studies between paclitaxel (Taxol) and OC144-093 - A new modulator of MDR in cancer chemotherapy
ES Guns et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2002)
The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil
M Masuda et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2002)
Multidrug resistance in cancer: Role of ATP-dependent transporters
MM Gottesman et al.
NATURE REVIEWS CANCER (2002)
分享论文
